Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dasatinib First-Line Treatment in Gastrointestinal Stromal Tumors. A Multi Center Phase II Trial

NCT00568750 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT00568750
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00568750 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dasatinib First-Line Treatment in Gastrointestinal Stromal Tumors. A Multi Center Phase II Trial
Lead sponsor
Swiss Cancer Institute
Phase
Phase 2
Overall status
Completed
Start date
January 22, 2008
Completion date
May 16, 2018
Enrollment
47 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal stromal tumor